Polypoidal Choroidal Vasculopathy Aflibercept Polypoidal Choroidal Vasculopathy Indocyanine Green Angiography Polyp Regression
Conditions
Interventions
received a fix dosing intravitreous 2-
mg aflibercept: monthly injection for 3 doses and then repeat injections at an 8-
week interval
Active Comparator Drug
Sponsors
Bayer Thai Co., Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Thai nationality • Age of ≥18 years • Diagnosis of treatment-naïve PCV in either eye (PCV is defined as a presence of hyperfluorescent polypoidal lesion with or without branching vascular network or collateral vessels on ICGA. If any participant presents with bilateral PCV, both eyes can be considered as study eyes)
Exclusion criteria
Exclusion criteria: • Presence of co-existing vision threatening conditions in the study eye e.g., diabetic retinopathy, retinal vascular occlusion, neovascular age-related macular degeneration • Good quality imaging could not be obtained due to the presence of cataract or other ocular media abnormalities • Contraindicate for FFA or ICGA due to the following conditions: • Allergic to fluorescein or indocyanine green dye • Allergic to iodine or seafood • Impaired kidney or liver functions • Not able to follow up according to the study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Timing of complete absence of polypoidal lesions on ICGA within 52 weeks after a fix dosing intravitreous aflibercept ICGA image | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of complete absence of polypoidal lesions on ICGA at 6 month and 1 year following a fix dosing intravitreous aflibercept ICGA image | — |
Countries
Thailand
Contacts
Public ContactVoraporn Chaikitmongkol
Faculty of medicine, Chiang Mai university
Outcome results
None listed